Overview and Highlights
September 2026 was a licensing-heavy month worth a combined multi-billion-dollar total, with Novartis, Roche/Genentech and GSK all striking a wave of cross-border deals. The headline transaction was Novartis's up to $3.2 billion option-and-license deal with South Korea's Alteogen for subcutaneous drug-delivery technology, closely followed by Roche's $1.53 billion bet on Simcere Zaiming's trispecific antibody and Novo Nordisk's up to $1.4 billion oral-macrocycle pact with fellow Danish biotech Orbis Medicines.
Private equity and Venture Financing was headlined by Frazier Life Sciences’ $1.1B oversubscription and Luma Group’s $410 million close to the inaugural LumaBio Fund 1, followed by Encoded Therapeutics $275 million Series F, Solstice Oncology’s $255 million Series A, and Sing Therapeutic’s $123 million Series C.
The IPO window remained brisk, headlined by Electra Therapeutics' upsized $350 million offering and AbbVie-backed ADARx Pharmaceuticals' Nasdaq filing, while a wave of reverse mergers — North Immunology into Aethlon Medical and Marea Therapeutics into Lisata Therapeutics — gave more private biotechs a path to the public markets.
>$5B M&A Deals
No strategic pharma-to-pharma M&A transaction exceeding $5 billion was signed and announced in September 2026. The month's largest single number attached to any deal was Apollo Global Management's reported ~$20 billion pursuit of Johnson & Johnson's DePuy Synthes orthopedics unit — a private equity transaction still under negotiation (not yet signed) as of month-end, but could be settled in the new few weeks
<$5B M&A Deals
1 | Novartis Inks Up to $3.2B Option-and-License Deal with Alteogen for Subcutaneous Drug Delivery Technology | Licensing/Partnership
Novartis, a leading global pharmaceutical company out of Basel, has entered into an option and license agreement with South Korea's Alteogen worth up to $3.2 billion for their ALT-B4 (berahyaluronidase alfa) technology, a proprietary recombinant human hyaluronidase that converts intravenous biologics into more convenient and rapid subcutaneous (SC) formulations. Although Alteogen did not disclose an upfront fee, the deal’s total value comprises of option exercise fees, development and commercial milestones, and royalties on net sales as Novartis will gain options for exclusive global rights to develop several subcutaneous products using the platform. This agreement is the fourth and largest ALT-B4 licensing deal in 2026, following deals with Biogen for up to $579 million and Tesaro, a GSK subsidiary, for up to $285 million, underscoring Alteogen’s rapid growth in the face of Halozyme’s ENHANZE platform, its major competitor in drug-delivery.
Simcere Zaiming, an oncology-focused subsidiary of China's Simcere Pharmaceutical Group, has entered into an exclusive global licensing agreement with Roche for SIM0660, a preclinical tri-specific antibody targeting CD79a, CD19 and CD3 with therapeutic potential across B-cell-mediated diseases. Roche is paying $75 million upfront and will gain exclusive global rights to develop, manufacture and commercialize the antibody, with Simcere Zaiming eligible for up to $1.53 billion in total payments plus tiered royalties on net sales. SIM0660 reflects growing investment across various tri-specific B-cell targeting antibodies, with applications in both oncology and autoimmune disease. The deal is Simcere’s sixth out-licensing transaction, potentially exceeding $6.1 billion in aggregate, and Roche's third Asia-based biotech partnership within an eight-day span following Roche’s Genentech deals in weight loss and ADC therapy development.
Novo Nordisk (recently rebranded to Novo) has entered a strategic collaboration and license agreement with fellow Danish biotech Orbis Medicines to discover and develop next-generation oral macrocycle therapeutics for cardiometabolic diseases. Orbis is eligible to receive up to $1.4 billion in upfront and development and commercial milestone payments, plus tiered royalties on future sales, and Novo will also make a separate strategic investment in the privately held biotech. The collaboration will use Orbis's “nGen” platform, combining generative AI, a lab-in-the-loop model, and experimental macrocycle datasets, to design orally bioavailable macrocycles, "nCycles," for therapeutic targets. This deal marks Orbis's first Big Pharma partnership since being founded by Novo Holdings in 2021 and completing seed and series A rounds in 2024 and 2025, respectively.
4 | GSK Pens Up to $1.3B Deal with Hutchmed for KRAS-EGFR Cancer Candidate | Biotech
GSK has entered a co-development and licensing agreement with Hutchmed for ex-China rights to HMPL-A830, a preclinical and first-in-class “antibody-targeted therapy conjugate” that pairs an EGFR-targeting antibody with a KRAS inhibitor payload, aimed initially at colorectal, pancreatic and lung cancers. Under the terms, Hutchmed will receive a $110 million upfront payment and is eligible for total payments up to $1.3 billion including development, regulatory and commercial milestones plus tiered royalties on net sales. The global phase 1/2 development will be led by HUTCHMED in China, expected to begin in late 2026, after which GSK assumes responsibility for subsequent development and commercialization outside Mainland China, Hong Kong, Macau and Taiwan.
5 | Roche Bets Up to $1B on Dualitas Therapeutics to Discover Novel Bispecific Antibodies | Biotech
Roche has entered into a research collaboration and license agreement with Dualitas Therapeutics worth up to $1 billion to discover and develop bispecific antibodies (“BsAb”) for immunology and inflammation diseases. Dualitas, using its DualScreen Bispecific Discovery Engine, will functionally screen more than 300,000 novel BsAb combinations, receiving $36.5 million upfront and eligible for research, development, and commercial milestone payments in addition to tiered royalties. Roche will be responsible for all subsequent preclinical development, regulatory, manufacturing and commercialization efforts. The deal extends Roche's bispecific antibody franchise (Columvi, Hemlibra, Lunsumio, & Vabysmo) into new potential immunology and inflammation indications.
6 | Menarini Signs Up to $843M Deal for Gan & Lee's Biweekly GLP-1 Bofanglutide in Europe | Pharma
Italy's Menarini Group has signed an exclusive licensing agreement with China's Gan & Lee Pharmaceuticals for European rights to bofanglutide, a GLP-1 receptor agonist dosed once every two weeks (half the frequency of most weekly GLP-1 drugs) for obesity and overweight adults. Gan & Lee is eligible for a €62 million (~$72 million) upfront payment and up to €664 million (~$771 million) in milestones, with an aggregate potential value of up to $726 million (~$843 million) in addition to royalties. Menarini will handle regulatory submissions and commercialization across 39 European markets, the EU-27 plus the UK, Switzerland, Norway, Iceland, Liechtenstein and Balkan countries, while Gan & Lee runs the global Phase 3 program. Bofanglutide has already met primary endpoints in a China Phase 3 study and US Phase 2 study.
GSK has agreed to acquire full global rights to a preclinical trispecific T-cell engager (TCE) for multiple myeloma from China-based Chimagen Biosciences, in a deal with a total potential value of up to $750 million in success-based development and commercial milestones and an undisclosed upfront fee. GSK plans to enter Phase 1 trials in 2027, hoping to demonstrate a more durable response and improved tolerability compared to existing TCEs that will aid increased and earlier adoption in treatment. This is the second asset GSK has acquired from Chimagen in under two years, following a 2024 deal worth up to $850 million for a separate CD19/CD20-targeted TCE in autoimmune and B-cell malignancy indications.
Fortrea has signed a definitive agreement to acquire the Early Phase Services division of fellow CRO Worldwide Clinical Trials in an all-cash transaction valued at approximately $45 million. The acquisition includes a 60,000-square-foot GLP-compliant bioanalytical laboratory in Austin, Texas, a 200-bed GCP-compliant clinical pharmacology unit in San Antonio, and a biospecimen storage facility in Pflugerville, Texas. The deal adds in-house large- and small-molecule bioanalytical capabilities to Fortrea's Clinical Pharmacology Services unit and expands its North American early-phase footprint, while freeing Worldwide Clinical Trials to concentrate investment on its growing late-stage oncology, neuroscience, internal medicine and rare disease business.
Top Precision Medicine IPOs (By Value)
1 | Electra Therapeutics Raises $350M in Upsized IPO to Fund Registrational HLH Trial | Biotech
Electra Therapeutics, a late clinical-stage biopharmaceutical company developing precision medicines targeting signal regulatory proteins (SIRP) for immune-mediated diseases and cancer, priced an upsized IPO of 23.33 million shares at $15.00 each, for expected gross proceeds of approximately $350 million. This was above the roughly $325 million the company had targeted in its Sept. 14 prospectus, and shares began trading on the Nasdaq Global Select Market on September 18 under the ticker "ETRA" before slipping ~12% and closing at $13.25. Ipsoprubart (ELA026) is the companies lead candidate and is currently in a registrational trial for secondary hemophagocytic lymphohistiocytosis, a rare and often life-threatening immune disorder with no approved treatments, in addition to a Phase 1 clinical trial for patients with relapsed/refractory T-cell and natural-killer malignancies. The San Francisco-based company also has a secondary clinical-stage candidate, ELA822, targeting a variety of chronic T cell-mediated diseases.
Nasdaq-listed Lisata Therapeutics has acquired privately held Marea Therapeutics in an all-stock transaction, taking on Marea's pipeline of cardioendocrine assets after Lisata's own oncology-focused merger attempt collapsed and led to major layoffs earlier this year. The transaction is paired with an oversubscribed $225 million private placement led by RA Capital Management, Forbion, Third Rock Ventures and other institutional investors, focused on advancing MAR001/MAR005 (for severe hypertriglyceridemia) and MAR002 (for acromegaly) through Phase 2 trials and key clinical milestones. Both studies are expected to present topline data in Q4 2027, and Marea CEO Josh Lehrer will become President and COO of the combined Lisata Therapeutics.
3 | North Immunology Goes Public via Reverse Merger with Aethlon Medical, Raising $180M | Biotech
North Immunology, a private biotech incubated inside ADAR1 Capital Management, will go public through an all-stock reverse merger with Nasdaq-listed Aethlon Medical, operating under North Immunology, Inc. and with the Nasdaq ticker “NTRX.” The deal provides an approximate $180 million in proceeds, led by Bain Capital Life Sciences and Janus Henderson Investors, and is expected to advance the development of NOR-101, a half-life-extended anti-IL-13/anti-IL-18 bispecific antibody, into Phase 1a trials for atopic dermatitis (eczema) in early 2027 and subsequent Phase 1b/2a studies. North Immunology shareholders will own roughly 95.25% of the combined company at a pro forma equity value of ~$346 million, with Aethlon shareholders retaining the remainder plus a contingent value right tied to Aethlon's legacy Hemopurifier business.
4 | AbbVie-Backed ADARx Pharmaceuticals Files for Nasdaq IPO to Fund siRNA Pipeline | Biotech
ADARx Pharmaceuticals, a late-clinical-stage biotech developing next-generation siRNA therapeutics, filed an S-1 with the SEC on September 4 for a proposed IPO on the Nasdaq Global Market under the ticker "ADRX." The San Diego-based company's pipeline includes three clinical-stage programs, most advanced is onvuzosiran, FDA fast-tracked and in Phase 3 for hereditary angioedema, plus two preclinical programs targeting obesity and neurodegenerative disease. ADARx is backed by a 2025 AbbVie collaboration that included a $335 million upfront payment, up to $385 million in option payments, and up to $7.45 billion in potential milestones. J.P. Morgan, Morgan Stanley, TD Cowen, UBS Investment Bank and LifeSci Capital are serving as underwriters. The offering has not been priced as of this writing.
Major Private Equity & Venture Capital Activity
1 | Frazier Life Sciences Tops Up Public Biotech Fund by $1.1B+, Bringing Total to $2.8B | Biotech
Frazier Life Sciences has raised more than $1.1 billion in additional capital commitments for its long-only, public fund dedicated to small- and mid-cap biotech companies navigating volatility and liquidity, bringing the fund's total committed capital to roughly $2.8 billion since its 2021 launch. Several of Frazier’s largest positions have been acquired such as Verona Pharma by Merck for $10 billion and Alpine Immune Sciences by Vertex Pharmaceuticals for $4.9 billion. While designed primarily to invest in public companies, the fund retains flexibility to back later-stage private biotechs through crossover financings. Frazier Life Sciences also manages over $6.9 billion when including its additional Venture Fund.
2 | Encoded Therapeutics Raises $275M Series F to Advance Dravet Syndrome Gene Therapy | Biotech
Encoded Therapeutics has closed a $275 million Series F financing co-led by GV (Google Ventures) and an undisclosed healthcare fund, with participation from ARCH Venture Partners, Braidwell, Farallon Capital, Illumina Ventures, Janus Henderson, SoftBank Vision Fund 2 and others. Proceeds will fund a pivotal study of ETX101, a one-time gene-regulation therapy, in infants and young children with SCN1A-positive Dravet syndrome, plus an expansion study in children up to age 18, and a build-out of the company's internal GMP manufacturing capacity and pipeline advancement for neurological disease (including ETX301 for post-amputation neuroma pain.) Interim Phase 1/2 data for ETX101 presented at the European Epilepsy Congress showed “substantial and sustained seizure frequency reductions” in addition to developmental gains.
3 | Solstice Oncology Launches with $225M Series A for Neoadjuvant Immuno-Oncology Therapy | Biotech
Solstice Oncology emerged from stealth with a $225 million Series A led by RA Capital Management, joined by Canaan Partners, Forbion and other investors. The Boston-based company is advancing porustobart, a second-generation Fc-enhanced CTLA-4 antibody licensed from China's Harbour BioMed, in a Phase 2 trial combined with pembrolizumab in the neoadjuvant setting for microsatellite-stable stage II–III colon cancer, plus a second undisclosed indication. The Phase 2 colon cancer trial is expected to open for enrollment in early Q4 2026, targeting a large segment of colon cancer patients whom have yet to benefit from immunotherapy, and the company believes porustobart’s mechanism can be effective across various tumor types.
Sling Therapeutics closed a $123 million Series C financing led by Forbion, with participation from existing backer TPG Life Sciences Innovations and new investor Sectoral Asset Management. Proceeds will support the global Phase 3 ORBIT trial of linsitinib, an oral small-molecule IGF-1R inhibitor for thyroid eye disease (TED), which would be the first oral option in a category currently treated with infused or injectable drugs like Amgen's Tepezza. The trial, targeting 120 patients, is evaluating linsitinib's ability to reduce proptosis over 24 weeks, and follows a completed Phase 2b/3 trial that assisted in FDA fast-track designation.
.png)
.png)
